Show simple item record

dc.contributor.authorSchache, AG
dc.contributor.authorPowell, NG
dc.contributor.authorCuschieri, KS
dc.contributor.authorRobinson, M
dc.contributor.authorLeary, S
dc.contributor.authorMehanna, H
dc.contributor.authorRapozo, D
dc.contributor.authorLong, A
dc.contributor.authorCubie, H
dc.contributor.authorJunor, E
dc.contributor.authorMonaghan, H
dc.contributor.authorHarrington, KJ
dc.contributor.authorNutting, CM
dc.contributor.authorSchick, U
dc.contributor.authorLau, AS
dc.contributor.authorUpile, N
dc.contributor.authorSheard, J
dc.contributor.authorBrougham, K
dc.contributor.authorWest, CML
dc.contributor.authorOguejiofor, K
dc.contributor.authorThomas, S
dc.contributor.authorNess, AR
dc.contributor.authorPring, M
dc.contributor.authorThomas, GJ
dc.contributor.authorKing, EV
dc.contributor.authorMcCance, DJ
dc.contributor.authorJames, JA
dc.contributor.authorMoran, M
dc.contributor.authorSloan, P
dc.contributor.authorShaw, RJ
dc.contributor.authorEvans, M
dc.contributor.authorJones, TM
dc.date.accessioned2017-04-10T15:29:43Z
dc.date.issued2016-11-15
dc.identifier.citationCancer research, 2016, 76 (22), pp. 6598 - 6606
dc.identifier.issn0008-5472
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/570
dc.identifier.eissn1538-7445
dc.identifier.doi10.1158/0008-5472.can-16-0633
dc.description.abstractA rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence has occurred throughout the developed world, where it has been attributed to an increasing impact of human papillomavirus (HPV) on disease etiology. This report presents the findings of a multicenter cross-sectional retrospective study aimed at determining the proportion of HPV-positive and HPV-negative OPSCC within the United Kingdom. Archival tumor tissue blocks from 1,602 patients previously diagnosed with OPSCC (2002-2011) were collated from 11 centers. HPV status was determined with three validated commercial tests to provide valid data for 1,474 cases in total. Corresponding national incidence data from the same decade were obtained from UK Cancer registries. The overall proportion of HPV+ OPSCC between 2002 and 2011 was 51.8% [95% confidence interval (CI), 49.3-54.4], and this remained unchanged throughout the decade [unadjusted RR = 1.00 (95% CI, 0.99-1.02)]. However, over the same period, the incidence of OPSCC in the broader UK population underwent a 2-fold increase [age-standardized rate 2002: 2.1 (95% CI, 1.9-2.2); 2011: 4.1 (95% CI, 4.0-4.3)]. Although the number of OPSCCs diagnosed within the United Kingdom from 2002 to 2011 nearly doubled, the proportion of HPV+ cases remained static at approximately 50%. Our results argue that the rapidly increasing incidence of OPSCC in the United Kingdom cannot be solely attributable to the influence of HPV. The parallel increase in HPV+ and HPV- cases we documented warrants further investigation, so that appropriate future prevention strategies for both types of disease can be implemented. Cancer Res; 76(22); 6598-606. ©2016 AACR.
dc.formatPrint-Electronic
dc.format.extent6598 - 6606
dc.languageeng
dc.language.isoeng
dc.publisherAMER ASSOC CANCER RESEARCH
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectPapillomaviridae
dc.subjectPapillomavirus Infections
dc.subjectOropharyngeal Neoplasms
dc.subjectFemale
dc.subjectMale
dc.subjectUnited Kingdom
dc.titleHPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology.
dc.typeJournal Article
dcterms.dateAccepted2016-07-17
rioxxterms.versionofrecord10.1158/0008-5472.can-16-0633
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer research
pubs.issue22
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume76
pubs.embargo.terms12 months
icr.researchteamTargeted Therapy
dc.contributor.icrauthorHarrington, Kevin


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record